Welcome to our dedicated page for Innovate news (Ticker: VATE), a resource for investors and traders seeking the latest updates and insights on Innovate stock.
INNOVATE Corp. (NYSE: VATE) generates news across its three reported segments: Infrastructure, Life Sciences and Spectrum. As a holding company with operating subsidiaries and equity method investments, its disclosures cover developments in structural steel construction, medical technology, aesthetic devices and over-the-air broadcasting.
News about the Infrastructure segment often focuses on DBM Global Inc., a family of companies providing integrated steel construction services. Coverage includes project activity, revenue by segment, backlog levels and cash dividends paid by DBM Global to its stockholders, with INNOVATE identified as the largest stockholder.
In Life Sciences, INNOVATE’s news highlights regulatory and commercial milestones at portfolio companies such as MediBeacon Inc. and R2 Technologies, Inc. Releases have detailed U.S. Food and Drug Administration approval for MediBeacon’s TGFR system, approvals in China for the Transdermal GFR System and Lumitrace injection, and growth in R2’s Glacial Skin CryoAesthetics platforms and global system sales.
The Spectrum segment generates updates on broadcasting operations, including revenue trends, new network launches and datacasting initiatives using ATSC 3.0 technology. INNOVATE has reported on the launch of ATSC 3.0 stations for a large mobile carrier and efforts to expand reach with additional networks.
Investors and followers of VATE can use this news feed to review INNOVATE’s quarterly earnings releases, Form 8-K announcements, refinancing transactions, segment performance commentary and major events at DBM Global, MediBeacon and R2. Regular updates provide a consolidated view of how developments in each segment contribute to the overall INNOVATE portfolio.
INNOVATE (NYSE: VATE) said DBM Global Inc., its operating subsidiary, will pay a $5.0 million cash dividend (about $1.30 per share) on Feb 24, 2026 to stockholders of record as of Feb 9, 2026. INNOVATE, as DBMG’s largest stockholder, expects to receive roughly $4.6 million of the payout. Individual INNOVATE shareholders are not eligible for this dividend.
INNOVATE (NYSE:VATE) holds a 44.7% equity interest in MediBeacon, which received FDA approval on December 16, 2025 for the next‑generation MediBeacon® TGFR™ System including the new TGFR Reusable Sensor.
The TGFR System measures clearance of Lumitrace® (relmapirazin) transdermally to assess kidney function at the point of care. The reusable sensor is designed for patient comfort, reusability via a disposable adhesive ring, and lower cost versus the previously approved single‑use sensor. MediBeacon highlighted a lead JASN cover article (August 2025) and cites >700 preclinical publications. Early access commercialization at select academic medical centers in the US and China is expected to begin in Q1 2026.
INNOVATE Corp (NYSE: VATE) reported third quarter 2025 consolidated revenue of $347.1M, up 43.3% year-over-year, driven by Infrastructure growth. Total Adjusted EBITDA was $19.8M, up 17.9% year-over-year. Net loss attributable to common stockholders narrowed to $9.4M (loss per share $0.71).
Key operational items: DBM Global revenue rose to $338.4M (+45.4%) with adjusted backlog of $1.6B. MediBeacon received NMPA approval to sell the Transdermal GFR System in China and expects sales before year-end. The company completed refinancing transactions but missed milestone dates, triggering sales/strategic processes for DBMG and HC2 Broadcasting.
INNOVATE Corp (NYSE: VATE) will release its third quarter 2025 financial results on Wednesday, November 12, 2025 after market close. The company will host an earnings conference call the same day starting at 4:30 p.m. ET to review results, operations and strategy.
The call will be broadcast live on INNOVATE’s Investor Relations website at www.innovate-ir.com; listeners should visit the Investor Relations section at least 15 minutes early to register. A replay will be available approximately three hours after the call and remain accessible through November 26, 2025. Domestic and international dial-in numbers and conference/replay details are provided for live and replay access.
INNOVATE (NYSE: VATE) announced that MediBeacon received NMPA approval for Lumitrace (relmapirazin) injection, the fluorescent agent used with the MediBeacon Transdermal GFR System (TGFR).
The TGFR—comprised of Lumitrace injection, the TGFR Monitor and TGFR Sensor—will be available for sale in China before the end of the year. The company noted prior approvals: the MediBeacon TGFR including Lumitrace received FDA approval in January, and NMPA previously approved the TGFR Monitor and Sensor in February. MediBeacon formed a commercial and clinical partnership with Huadong Medicine in July 2019. The release highlights tGFR as a point-of-care measured GFR alternative to lab-based eGFR and mGFR, and cites China CKD prevalence at 11% of 1.4 billion.
INNOVATE (NYSE: VATE) announced that its operating subsidiary DBM Global will pay a cash dividend of approximately $8.8 million (about $2.28 per share) on November 10, 2025 to stockholders of record as of the close of business on October 27, 2025. As DBM Global's largest stockholder, INNOVATE expects to receive approximately $8.0 million of the total dividend. The announcement notes that INNOVATE's individual stockholders are not eligible to receive the DBM Global cash dividend.
INNOVATE Corp. (NYSE:VATE) announced exceptional Q2 2025 performance for its subsidiary R2 Technologies, developer of Glacial® Skin technology. R2 achieved an 88% year-over-year revenue growth in Q2 2025, with global system sales surging 125% compared to Q2 2024.
Key highlights include a 768% growth in demand outside North America for H1 2025, 115% increase in patient treatments, and 28% rise in monthly provider utilization. The company's digital presence showed remarkable growth with 823% above-industry-benchmark social media engagement, 52% quarter-over-quarter growth in social mentions, and 141% increase in website traffic.
The global non-invasive aesthetic market is projected to grow from $83.13 billion in 2025 to $238 billion by 2034, with a 12.4% CAGR.
INNOVATE Corp. (NYSE:VATE) reported Q2 2025 results with revenue declining 22.7% to $242.0 million from $313.1 million in Q2 2024. The company posted a net loss of $22.0 million ($1.67 per share) compared to net income of $14.1 million ($1.03 per share) in the prior year quarter.
Key segment performance includes: Infrastructure revenue decreased 23.6% to $233.1 million with a strong backlog of $1.3 billion; Life Sciences saw 88.2% revenue growth to $3.2 million with R2's system unit sales up 124.5%; Spectrum revenue declined to $5.7 million from $6.2 million.
The company completed significant refinancing transactions extending debt maturities, including exchange offers, convertible notes negotiations, and credit agreement amendments across multiple subsidiaries.
INNOVATE Corp. (NYSE: VATE) has successfully completed a comprehensive refinancing of its debt obligations, restructuring 81.7% of its total outstanding principal debt as of June 30, 2025. The transaction includes multiple components: exchange of $328.1M of existing senior secured notes for new 10.500% Senior Secured Notes due 2027, exchange of $48.7M convertible senior notes for new 9.5% Convertible Senior Secured Notes, and amendments to various credit facilities.
Key extensions include the company's revolving credit agreement to September 2026, CGIC note to April 2027, Spectrum Notes to September 2026, and R2 Technologies note to August 2026. The refinancing also involved exchanging preferred stock held by CGIC for additional note principal, resulting in a total CGIC note amount of $43.0M.
INNOVATE Corp. (NYSE:VATE) announced strong early results for its exchange offer of 8.5% Senior Secured Notes due 2026. The company received 99.41% participation (US$328,067,000 of US$330,000,000 outstanding), exceeding the minimum 98% requirement.
The new 10.5% Senior Secured Notes due 2027 will offer holders US$1,072.50 in principal per US$1,000 of existing notes, including a US$20 early exchange premium and US$52.50 additional principal for accrued interest. The company extended the Total Early Exchange Consideration eligibility through the August 13, 2025 expiration deadline.
The exchange includes amendments eliminating most restrictive covenants and subordinating remaining existing notes. Settlement is expected on August 15, 2025, subject to conditions including completion of previously announced Concurrent Transactions.
FAQ
What is the current stock price of Innovate (VATE)?
What is the market cap of Innovate (VATE)?
